Danirixin

Research use only, not for human use.

Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8).

Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8); blocks the CD11b upregulation with pIC50 of 6.05 and 6.3, respectively, in rat and human whole-blood studies; blocks the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide (ED50=1.4 mg/kg); orally active.COPD Phase 2 Clinical(In Vitro):Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.

Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.

——

GSK-1325756

GPCR/G Protein

Chemokine Receptor

CXCL8-CXCR2

Inflammation/Immunology

COPD

954126-98-8

441.9041

C19H21ClFN3O4S

>98% (HPLC)

DMSO: 8 mg/mL

ClC(C(S([C@H]1CCCNC1)(=O)=O)=C2O)=CC=C2NC(NC3=CC=CC(F)=C3C)=O

Urea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)-

(-20℃)

With Ice Pack

≥ 2 years